Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Mineralys Therapeutics (Nasdaq: MLYS) announced on November 26, 2025 that its Compensation Committee granted an inducement stock option covering 146,000 shares to one new non-executive employee on November 24, 2025.

The award was made under the company’s 2025 Employment Inducement Incentive Award Plan and was granted as an inducement material to the employee entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The option vests over four years: 25% on the first anniversary of the vesting commencement date (November 24, 2026) and 1/48th monthly thereafter, subject to continued service.

News Market Reaction

-0.55%

1 alert

-0.55% News Effect

On the day this news was published, MLYS declined 0.55%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option size: 146,000 shares Vesting schedule: 4 years Initial vesting: 25% +5 more

8 metrics

Inducement option size 146,000 shares Granted to one new non-executive employee on Nov 24, 2025

Vesting schedule 4 years Inducement stock option vests over four-year period

Initial vesting 25% Vests on first anniversary of vesting commencement date

Ongoing vesting rate 1/48th monthly Monthly vesting after first anniversary, subject to continued service

Vesting start date November 24, 2025 Vesting commencement date for the inducement option

Market cap $2,864,866,407 Pre-news market capitalization

52-week range $8.241–$47.65 Pre-news 52-week low and high

Price vs 52-week low 337.45% Pre-news price performance above 52-week low

Market Reality Check

Price: $31.93 Vol: Volume 1,476,404 is below...

normal vol

$31.93 Last Close

Volume Volume 1,476,404 is below the 20-day average of 1,743,671 ahead of this inducement award news. normal

Technical Price at $36.05 is trading above the 200-day MA of $23.29 and 24.34% below the 52-week high.

Peers on Argus

Peers showed mixed moves: IMVT +5.75%, VKTX +1.44%, CRNX +1.59%, XENE +0.51%, wh...

Peers showed mixed moves: IMVT +5.75%, VKTX +1.44%, CRNX +1.59%, XENE +0.51%, while SLNO declined 7.19%, suggesting today’s modest -1.44% move in MLYS was more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Nov 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 26	Inducement option grant	Neutral	-0.6%	Inducement stock option for 146,000 shares to a new employee.
Nov 10	Q3 earnings update	Positive	+17.0%	Strong cash position, reduced R&D spend, and NDA timing update.
Nov 07	Clinical data update	Positive	+17.0%	Lorundrostat CKD and hypertension data met endpoints with significant BP drops.
Nov 05	Investor conferences	Neutral	-6.7%	Participation in multiple healthcare investor conferences in Nov–Dec 2025.
Nov 03	Earnings call notice	Neutral	-4.1%	Scheduled Q3 2025 results release and conference call details.

Pattern Detected

Fundamental catalysts (clinical data, earnings/corporate updates) have recently coincided with strong positive moves, while conference scheduling and administrative items have seen flat-to-negative reactions.

Recent Company History

This announcement follows a series of more material updates. Earlier in November, Mineralys reported Q3 2025 results with cash of $593.6M, net loss of $36.9M, and expectations that cash funds operations into 2028. Clinical data for lorundrostat from Phase 2 and Phase 3 hypertension and CKD trials produced statistically significant blood pressure and UACR reductions, with NDA submission targeted for late 2025 or Q1 2026. Conference participation and earnings scheduling headlines saw weaker or negative price reactions compared with clinical and earnings results.

Market Pulse Summary

This announcement details a routine inducement stock option covering 146,000 shares granted to a new...

Analysis

This announcement details a routine inducement stock option covering 146,000 shares granted to a new non‑executive employee under Nasdaq Listing Rule 5635(c)(4), with vesting over four years. In context, more material drivers have recently included pivotal lorundrostat data and Q3 2025 results highlighting $593.6M in cash and progress toward an NDA. Investors may focus on upcoming regulatory milestones and any further equity or insider activity disclosed in future filings.

Key Terms

chronic kidney disease (CKD), obstructive sleep apnea (OSA), aldosterone, inducement stock option, +3 more

7 terms

chronic kidney disease (CKD) medical

"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"

Chronic kidney disease (CKD) is a long-term decline in the kidneys’ ability to filter waste and balance fluids and chemicals in the body, often progressing slowly over months or years; think of it as a filter that gradually becomes clogged and less effective. It matters to investors because CKD drives demand for drugs, dialysis, transplants, diagnostics and related medical devices, influences healthcare costs and reimbursement decisions, and is a common target for clinical trials and regulatory review.

obstructive sleep apnea (OSA) medical

"chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases"

A sleep disorder where a person repeatedly stops breathing or breathes very shallowly during sleep because the airway partly or fully closes, causing snoring, daytime tiredness, and other health risks. Investors care because it drives demand for medical devices, diagnostics, treatments, and ongoing healthcare costs—similar to a chronic equipment failure in a factory that reduces output and increases maintenance and regulatory oversight, affecting revenue, reimbursement and long‑term market growth.

aldosterone medical

"other diseases driven by dysregulated aldosterone, announced today that on"

Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.

inducement stock option financial

"granted an inducement stock option award covering 146,000 shares of"

An inducement stock option is a grant of the right to buy company shares given to a new or existing employee as a special hiring or retention incentive, similar to offering a signing bonus but paid in future stock. Investors care because these options can motivate managers to grow the business and align their interests with shareholders, while also increasing the total number of shares over time and potentially diluting existing ownership and earnings per share.

equity awards financial

"Plan, which provides for the granting of equity awards to new employees"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

Nasdaq Listing Rule 5635(c)(4) regulatory

"the employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

common stock financial

"stock option award covering 146,000 shares of Mineralys common stock to"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. Not financial advice.

RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 146,000 shares of Mineralys common stock to one new non-executive employee.

The award was granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of the award’s vesting commencement date, November 24, 2025, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.

Contact:
Investor Relations
investorrelations@mineralystx.com

FAQ

What did Mineralys Therapeutics (MLYS) announce on November 26, 2025 about a stock option grant?

Mineralys announced a grant of an inducement stock option covering 146,000 shares to one new non-executive employee, dated November 24, 2025.

Under which plan was the Mineralys (MLYS) inducement award granted?

The award was granted under the company’s 2025 Employment Inducement Incentive Award Plan.

What is the vesting schedule for the Mineralys (MLYS) 146,000-share option awarded November 24, 2025?

The option vests over four years: 25% on the first anniversary of November 24, 2025, then 1/48th of the total shares vest each month thereafter, subject to continued service.

Why did Mineralys (MLYS) use Nasdaq Listing Rule 5635(c)(4) for this award?

The company said the award was an inducement material to the new employee entering employment and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received the inducement award from Mineralys (MLYS) on November 24, 2025?

One new non-executive employee received the inducement stock option covering 146,000 shares.

Does the Mineralys (MLYS) announcement state any immediate dilution or financial impact from the 146,000-share option?

The announcement describes the grant and vesting schedule only and does not provide figures or commentary on dilution or immediate financial impact.